Evidence map›Paper›PMID 19477951›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2009

Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells.

Paul J Brighton, John McDonald, Anthony H Taylor, R A John Challiss, David G Lambert, Justin C Konje, Jonathon M Willets

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Differential Expression of CBCannabis and cannabinoid research · 2022
    Article
  4. Article
  5. Review
  6. Chemerin-induced arterial contraction is GVascular pharmacology · 2017
    Article
  7. Review
  8. CBAdvances in pharmacology (San Diego, Calif.) · 2017
    Review
  9. Article
  10. Article
  11. Why do cannabinoid receptors have more than one endogenous ligand?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012
    Review
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Paul J BrightonEndocannabinoid Research Group, Reproductive Sciences Section, Department of Cancer Studies, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, United Kingdom.
John McDonald
Anthony H Taylor
R A John Challiss
David G Lambert
Justin C Konje
Jonathon M Willets
University of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence highlights the importance of the endocannabinoid anandamide (AEA) as a key mediator in reproductive physiology. Current data suggest potential roles for AEA in gametogenesis, fertilization, and parturition. AEA exerts its actions through two G protein-coupled receptors, termed cannabinoid receptor 1 (CB1), and 2 (CB2), and the ligand-gated transient receptor potential vanilloid receptor type 1 (TRPV1) ion channel. At present, the cellular mechanism(s) and consequences of AEA signaling in reproductive tissues, especially the myometrium, are poorly understood. Here, we examine the expression of CB1, CB2, and TRPV1 in the human myometrial smooth muscle cell-line (ULTR) and characterize intracellular signaling after stimulation with AEA. Radioligand binding analysis revealed a total CB receptor expression of 76 +/- 24 fmol/mg protein, with both quantitative PCR and competition binding studies indicating a negligible CB2 component. AEA caused Galpha(i/o)-dependent inhibition of adenylate cyclase to reduce intracellular cAMP levels. In addition, AEA caused a 2.5- to 3.5-fold increase in ERK activation, which was ablated by inhibition of Galpha(i/o), phosphoinositide-3-kinase and Src-kinase activities, but not by inhibition of Ca(2+)/calmodulin-dependent protein kinase or protein kinase C activities. TRPV1 channel activation with capsaicin failed to activate ERK. Consistent with these findings, the selective agonists, arachidonyl-2-chloroethylamide (CB1) and L759656 (CB2), and selective antagonists AM251 (CB1) and JTE907 (CB2), provided pharmacological evidence that the ERK signaling pathway is activated through endogenously expressed CB1. These findings provide an insight into myometrial AEA signaling, highlighting a potential role for endocannabinoids in the regulation of gene expression in myometrial smooth muscle cells.

Indexed as

Arachidonic AcidsCell LineCell SurvivalEndocannabinoidsExtracellular Signal-Regulated MAP KinasesFemaleGene Expression RegulationGTP-Binding Protein alpha Subunits, Gi-GoHumansModels, BiologicalMuscle, SmoothMyometriumPolymerase Chain ReactionPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2anandamideArachidonic AcidsEndocannabinoidsExtracellular Signal-Regulated MAP KinasesGTP-Binding Protein alpha Subunits, Gi-GoPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID19477951
PMCPMC2737560
OpenAlexW1976488552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.